{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:37:08Z","timestamp":1740116228011,"version":"3.37.3"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1097\/spc.0b013e32833abc21","type":"journal-article","created":{"date-parts":[[2010,5,20]],"date-time":"2010-05-20T06:30:16Z","timestamp":1274337016000},"page":"121-126","source":"Crossref","is-referenced-by-count":3,"title":["Screening for prostate cancer: have we resolved the controversy?"],"prefix":"10.1097","volume":"4","author":[{"given":"Xiaoye","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique J","family":"Roobol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz H","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20211004","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/annonc\/mdl498","article-title":"Estimates of the cancer incidence and mortality in Europe in 2006","volume":"18","author":"Ferlay","year":"2007","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"R3-2-20211004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1464-410X.2003.04388.x","article-title":"The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening?","volume":"92","author":"Auvinen","year":"2003","journal-title":"BJU Int"},{"key":"R4-2-20211004","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc2351","article-title":"Prostate-specific antigen and prostate cancer: prediction, detection and monitoring","volume":"8","author":"Lilja","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"R5-2-20211004","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.urology.2009.02.016","article-title":"Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later","volume":"73","author":"Pienta","year":"2009","journal-title":"Urology"},{"key":"R6-2-20211004","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1464-410X.2007.07138.x","article-title":"The discovery of prostate-specific antigen","volume":"101","author":"Rao","year":"2008","journal-title":"BJU Int"},{"key":"R7-2-20211004","first-page":"159","article-title":"Purification of a human prostate specific antigen","volume":"17","author":"Wang","year":"1979","journal-title":"Invest Urol"},{"key":"R8-2-20211004","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/jama.284.11.1399","article-title":"Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection","volume":"284","author":"Ross","year":"2000","journal-title":"JAMA"},{"key":"R9-2-20211004","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3322\/CA.2007.0017","article-title":"Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues","volume":"58","author":"Smith","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"R10-2-20211004","first-page":"545","article-title":"Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990","volume":"180","author":"Jones","year":"1995","journal-title":"J Am Coll Surg"},{"key":"R11-2-20211004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10552-007-9083-8","article-title":"Quantifying the role of PSA screening in the US prostate cancer mortality decline","volume":"19","author":"Etzioni","year":"2008","journal-title":"Cancer Causes Control"},{"key":"R12-2-20211004","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1464-410X.2008.07502.x","article-title":"Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality","volume":"101","author":"Bartsch","year":"2008","journal-title":"BJU Int"},{"key":"R13-2-20211004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1007\/s11606-008-0785-8","article-title":"Screening, treatment, and prostate cancer mortality in the Seattle area and Connecticut: fifteen-year follow-up","volume":"23","author":"Lu-Yao","year":"2008","journal-title":"J Gen Intern Med"},{"key":"R14-2-20211004","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0022-5347(05)67912-8","article-title":"Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening","volume":"163","author":"Merrill","year":"2000","journal-title":"J Urol"},{"key":"R15-2-20211004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1008965617078","article-title":"Prostate cancer in Saskatchewan Canada, before and during the PSA era","volume":"11","author":"Skarsgard","year":"2000","journal-title":"Cancer Causes Control"},{"key":"R16-2-20211004","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ijc.1260","article-title":"International trends in prostate-cancer mortality in the \u2018PSA ERA\u2019","volume":"92","author":"Oliver","year":"2001","journal-title":"Int J Cancer"},{"issue":"Suppl 2","key":"R17-2-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1464-410X.2003.04389.x","article-title":"The story of the European Randomized Study of Screening for Prostate Cancer","volume":"92","author":"Schr\u00f6der","year":"2003","journal-title":"BJU Int"},{"key":"R18-2-20211004","doi-asserted-by":"crossref","first-page":"273S","DOI":"10.1016\/S0197-2456(00)00098-2","article-title":"Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial","volume":"21","author":"Prorok","year":"2000","journal-title":"Control Clin Trials"},{"key":"R19-2-20211004","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"key":"R20-2-20211004","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"key":"R21-2-20211004","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1464-410X.2008.08214.x","article-title":"Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial","volume":"102","author":"Grubb","year":"2008","journal-title":"BJU Int"},{"key":"R22-2-20211004","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2009.07.018","article-title":"Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)","volume":"56","author":"Roobol","year":"2009","journal-title":"Eur Urol"},{"key":"R23-2-20211004","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/jnci\/djp533","article-title":"Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam.","volume":"102","author":"Wever","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 2","key":"R24-2-20211004","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1464-410X.2003.04407.x","article-title":"Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening","volume":"92","author":"Ciatto","year":"2003","journal-title":"BJU Int"},{"key":"R25-2-20211004","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/S0140-6736(08)60933-2","article-title":"Primary endpoints for randomised trials of cancer therapy","volume":"371","author":"Cuzick","year":"2008","journal-title":"Lancet"},{"key":"R28-2-20211004","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1572-0241.2008.01875.x","article-title":"Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update","volume":"103","author":"Hewitson","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R29-2-20211004","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jnci\/95.12.868","article-title":"Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer","volume":"95","author":"Draisma","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R30-2-20211004","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/jnci\/94.13.981","article-title":"Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends","volume":"94","author":"Etzioni","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R31-2-20211004","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/jnci\/94.13.958","article-title":"Understanding and appreciating overdiagnosis in the PSA era","volume":"94","author":"Yao","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R32-2-20211004","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/pros.20840","article-title":"A graphical device to represent the outcomes of a logistic regression analysis","volume":"68","author":"Kranse","year":"2008","journal-title":"Prostate"},{"key":"R34-2-20211004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eururo.2009.08.025","article-title":"A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer","volume":"57","author":"Roobol","year":"2010","journal-title":"Eur Urol"},{"key":"R35-2-20211004","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.eururo.2005.11.005","article-title":"Tumour features in the control and screening arm of a randomized trial of prostate cancer","volume":"50","author":"Postma","year":"2006","journal-title":"Eur Urol"},{"key":"R36-2-20211004","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.eururo.2008.01.048","article-title":"Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng\/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC","volume":"53","author":"Schr\u00f6der","year":"2008","journal-title":"Eur Urol"},{"key":"R37-2-20211004","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MOU.0b013e328329a2d0","article-title":"Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer","volume":"19","author":"Schr\u00f6der","year":"2009","journal-title":"Curr Opin Urol"},{"key":"R38-2-20211004","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.eururo.2009.10.031","article-title":"Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies","volume":"57","author":"Schr\u00f6der","year":"2010","journal-title":"Eur Urol"},{"key":"R39-2-20211004","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1464-410X.2009.08627.x","article-title":"Screening: should more biopsies be taken in larger prostates?","volume":"104","author":"van Leeuwen","year":"2009","journal-title":"BJU Int"},{"key":"R40-2-20211004","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1470-2045(04)01384-1","article-title":"Active surveillance: towards a new paradigm in the management of early prostate cancer","volume":"5","author":"Parker","year":"2004","journal-title":"Lancet Oncol"},{"key":"R41-2-20211004","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.eururo.2007.05.011","article-title":"Prospective validation of active surveillance in prostate cancer: the PRIAS study","volume":"52","author":"van den Bergh","year":"2007","journal-title":"Eur Urol"},{"key":"R42-2-20211004","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2009.24.2180","article-title":"Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer","volume":"28","author":"Klotz","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201009000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:18:52Z","timestamp":1740097132000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201009000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e32833abc21","relation":{},"ISSN":["1751-4258"],"issn-type":[{"type":"print","value":"1751-4258"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}